Da-Wei Shi (Dawei Shi)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Venous Thromboembolism

Drug Administration

Advanced Non Small Cell Lung Cancer

Atrial Fibrillation

Top Venues

Journal of clinical pharmacy and therapeutics

British journal of clinical pharmacology

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Xiao-Shan Zhang, Ye-Li Chen, Yu-Zhen Wang, Chuang Chen, Yao-Jie Chen, Fang-Min Xu, Ying Dai, Da-Wei Shi, Guan-Yang Lin, Xu-Ben Yu, Dan-Zhu Xiang, Chun-Hong Zhang
Model-based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non-complicated MRSA infection. British journal of clinical pharmacology (2023)
Haixia Shao, Da-Wei Shi, Ying Dai
Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System. British journal of clinical pharmacology (2022)
Ziye Zhou, Chenxiang Wang, Lili Ying, Mi Jin, Fangfang Zhang, Da-Wei Shi
Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database. Journal of clinical pharmacy and therapeutics 46 (4) (2021)
Ying Dai, Yingying Wang, Yifan Zeng, Chunhong Zhang, Ziye Zhou, Da-Wei Shi
Linezolid and the risk of lactic acidosis: Data mining and analysis of the FDA Adverse Event Reporting System. Journal of clinical pharmacy and therapeutics 45 (6) (2020)
Da-Wei Shi, Ziye Zhou, Ying Dai, Xiaofeng Pan, Qinqin Cao
Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis. Clinical drug investigation 39 (9) (2020)
Xiaofeng Pan, Ziye Zhou, Xiangxiang Jin, Da-Wei Shi
Clinical characteristics and risk factors of severe hyponatremia in cirrhotic patients treated with terlipressin. Journal of clinical pharmacy and therapeutics 45 (1) (2019)